Evidence of all types, from real-world and clinical to HEOR and patient experience, is essential to the success of healthcare innovations, so evidence-generation planning must be a top priority. Yet, too often, it’s treated as something that happens after development, an activity to fill data gaps rather than a strategic exercise to guide decisions. A comprehensive evidence package for a product launch includes clinical, real-world, HEOR, patient centered and competitive evidence, each of them working together to form a coherent product value story. Each evidence type acts as a critical lever by influencing major decision gates such as regulatory approval, payer reimbursement, clinician adoption, and patient uptake. Hence, effective coordination in evidence generation becomes a strategic advantage guiding drug development, supporting market access and helps sustain long-term product success. Evidence doesn’t emerge by chance. It requires foresight, structure, and collaboration. When approached early and thoughtfully, evidence generation planning (EGP) transforms into a roadmap that connects clinical research, regulatory needs, payer expectations, and ultimately, patient outcomes.
At its core, EGP is about asking the right questions before diving into data collection. What do we need to know to demonstrate the true value of this therapy? Which endpoints will matter most to clinicians and patients? How will payers evaluate real-world benefit? When these questions are built into a plan, rather than addressed reactively, the resulting evidence tells a stronger, clearer story. That story becomes the backbone for regulatory approval, health technology assessments (HTAs), and sustained market access.
Global health authorities have underscored this shift towards proactive, integrated evidence strategies. The U.S. Food and Drug Administration (FDA) has highlighted the value of real-world evidence in regulatory decision-making, urging sponsors to plan for real-world data collection as part of development programs1. Similarly, the European Medicines Agency (EMA) and EUnetHTA have advocated for early, joint scientific advice processes that align evidence generation with both regulatory and payer requirements2. The National Institute for Health and Care Excellence (NICE) has also emphasized early dialogue and real-world data planning in its Evidence Standards Framework for Digital Health Technologies (2022), promoting the principle that evidence should evolve across a product’s lifecycle3.
The challenge, however, lies in coordination. Different teams such as clinical, HEOR, regulatory, market access often work in parallel, each generating evidence that fits their immediate goals. Without alignment, the result can be duplication, missed opportunities, or evidence that doesn’t speak to stakeholder priorities. Integrated evidence generation planning brings these efforts together under one narrative, ensuring that every study and dataset contributes to a coherent story of value. As the ISPOR–ISPE Joint Task Force on Real-World Evidence (2017) observed, collaboration and standardization in evidence generation are essential for building trust in data used across regulatory and reimbursement contexts4.
Organizations are moving toward living evidence plans and dynamic frameworks that evolve as assets mature. These plans identify gaps, track progress, and adapt as the landscape changes. They help teams move beyond “what data do we have?” to “what story are we building and is it resonating with those who need to hear it?”
At GPI, our evidence generation planning offering spans the full development continuum:
- Early Pipeline (Preclinical–Phase 1):
Target product profile refinement, unmet need identification, early payer expectations, competitor evidence landscape reviews. - Mid-Stage Development (Phase 2–3):
Endpoint selection, trial design shaping, RWE strategy development, evidence gap analyses, early HTA/payer advisory preparation. - Late Stage and Launch:
HTA readiness assessments, value dossier development, pricing & access modelling, real-world evidence generation planning. - Post-Launch Lifecycle:
RWE study design support, ongoing evidence plan optimisation, update of dossiers and value narratives based on emerging data.
Throughout these stages, GPI’s blend of domain expertise, analytical tools, and structured methodologies ensures that every piece of evidence collected is purposeful, defensible, and aligned with market expectations.
At GPI, we believe that effective evidence generation starts with clarity on the purpose, the questions, and the path forward. Our work in market access and data-driven strategy has shown that when evidence planning is done early and collaboratively, it bridges silos, saves time, and ultimately leads to stronger, more compelling value communication. Because in the end, good evidence isn’t about collecting more data but it’s about generating the right insights to create real-world impact.
References:
- U.S. Food and Drug Administration (FDA). Framework for Real-World Evidence Program (2018)
- European Medicines Agency (EMA) and EUnetHTA. Collaboration on Evidence Generation (2020)
- National Institute for Health and Care Excellence (NICE). Evidence Standards Framework for Digital Health Technologies (2022)
- ISPOR–ISPE Joint Task Force. Real-World Evidence in Healthcare Decision-Making (2017)
